ÂÜÀòÂÒÂ×

Mary Jane Geiger, MD, PhD has 20 years of biopharmaceutical industry experience and has led all phases of clinical development. She serves as our Chief Medical Officer.

Dr. Geiger previously served as vice president, drug development services – cardiovascular, at ICON, a global clinical research organization. She provided cardio-metabolic and renal therapeutic area and rare disease consulting and drug development expertise to pharmaceutical and biotech clients, assisting them in the successful development and delivery of their drug development portfolio. She previously served as senior director, cardiovascular and metabolism at Regeneron Pharmaceuticals, a publicly-traded biopharmaceutical company; as vice president, clinical development at Relypsa, a private pharmaceutical company; and as medical fellow I, Lilly Diabetes at Eli Lilly and Company. During her tenure at Lilly, Dr. Geiger was responsible for clinical development of Trulicity® from post-Phase 1 through completion of pivotal clinical studies. She began her biopharmaceutical industry career at Merck in 2000, and before this was in private practice, a clinical trial investigator, IRB member and chairman of the department of internal medicine. Dr. Geiger earned her bachelor’s degree in biology from Marquette University, and her medical doctorate and Ph.D. from the Medical College of Wisconsin in Milwaukee, Wisconsin. She completed her internal medicine internship and residency at Duke University Medical Center with additional research in nephrology and cardiology, and has authored numerous scientific and clinical publications.